human bladder cancer cell lines ht1197  (ATCC)

Journal: Molecular cancer therapeutics

Article Title: Histone deacetylase inhibition has targeted clinical benefit in ARID1A mutated advanced urothelial carcinoma

doi: 10.1158/1535-7163.MCT-17-0957

Figure Lengend Snippet: A. Mutation plots of cell lines adapted from Nickerson, M L et al. “Molecular Analysis of Urothelial Cancer Cell Lines for Modeling Tumor Biology and Drug Response.” Oncogene (2016) (27) under a Creative Commons Attribution- NonCommercial-ShareAlike4.0 International License. Cell viabilities of UMUC3, T24 and HT1197 bladder cancer cell lines treated with increasing doses of B. Cisplatin, C. Panobinostat D. Belinostat, E. Tubastatin, and F. Mocetinostat. Dose response curves showing percent viability normalized to vehicle controls after 72 hours of treatment plotted against the logarithmic drug concentrations. Half-maximal inhibitory concentrations (IC50s) were calculated using GraphPad Prism. The error bars represent biological replicates.

Article Snippet: Cell culture and Cell viabilities Cell Culture Human bladder cancer cell lines HT1197, T24 and UMUC3, were obtained from ATCC between 2015 and 2018.

Techniques: Mutagenesis

Journal: Molecular cancer therapeutics

Article Title: Histone deacetylase inhibition has targeted clinical benefit in ARID1A mutated advanced urothelial carcinoma

doi: 10.1158/1535-7163.MCT-17-0957

Figure Lengend Snippet: Significantly enriched Hallmark gene sets in HT1197 cells treated with panobinostat for 48 hours

Article Snippet: Cell culture and Cell viabilities Cell Culture Human bladder cancer cell lines HT1197, T24 and UMUC3, were obtained from ATCC between 2015 and 2018.

Techniques:

Journal: Molecular cancer therapeutics

Article Title: Histone deacetylase inhibition has targeted clinical benefit in ARID1A mutated advanced urothelial carcinoma

doi: 10.1158/1535-7163.MCT-17-0957

Figure Lengend Snippet: Cell cycle changes by flow cytometry using 12 nM panobinostat in A. HT1197, B. UMUC3, and C. T24 vs vehicle treatment for 24 hours. D. Changes in percent population of cells quantified by graph pad prizm. The change in the cell population distribution was replicated for a total of three times. An unpaired student t-test to compare the percent population with and without treatment showed the changes in G0/G1 and G2/M populations to be statistically significant. The error bars represent biological replicates.

Article Snippet: Cell culture and Cell viabilities Cell Culture Human bladder cancer cell lines HT1197, T24 and UMUC3, were obtained from ATCC between 2015 and 2018.

Techniques: Flow Cytometry

Journal: Molecular cancer therapeutics

Article Title: Histone deacetylase inhibition has targeted clinical benefit in ARID1A mutated advanced urothelial carcinoma

doi: 10.1158/1535-7163.MCT-17-0957

Figure Lengend Snippet: A. Western blot to assess p21 levels in bladder cancer cell lines treated with panobinostat at 2 and 4 times the IC50 dose for 48 hours. This was repeated for a total of three times B. Western blot showing accumulation of gH2Ax marks in HT1197 upon treatment with panobinostat and belinostat. This was repeated for a total of three times. C. RT PCR to assess expression of TNFα, IFNβ1 and IFNα2 in HT1197 cells treated with panobinostat and belinostat. Results from three biological replicates are represented with error bars and the change in expression is tested for significance by the unpaired t-test (Graphpad Prism).

Article Snippet: Cell culture and Cell viabilities Cell Culture Human bladder cancer cell lines HT1197, T24 and UMUC3, were obtained from ATCC between 2015 and 2018.

Techniques: Western Blot, Reverse Transcription Polymerase Chain Reaction, Expressing

Journal: Molecular cancer therapeutics

Article Title: Histone deacetylase inhibition has targeted clinical benefit in ARID1A mutated advanced urothelial carcinoma

doi: 10.1158/1535-7163.MCT-17-0957

Figure Lengend Snippet: A. Mutation plots of cell lines adapted from Nickerson, M L et al. “Molecular Analysis of Urothelial Cancer Cell Lines for Modeling Tumor Biology and Drug Response.” Oncogene (2016) (27) under a Creative Commons Attribution- NonCommercial-ShareAlike4.0 International License. Cell viabilities of UMUC3, T24 and HT1197 bladder cancer cell lines treated with increasing doses of B. Cisplatin, C. Panobinostat D. Belinostat, E. Tubastatin, and F. Mocetinostat. Dose response curves showing percent viability normalized to vehicle controls after 72 hours of treatment plotted against the logarithmic drug concentrations. Half-maximal inhibitory concentrations (IC50s) were calculated using GraphPad Prism. The error bars represent biological replicates.

Article Snippet: Cell Culture Human bladder cancer cell lines HT1197, T24 and UMUC3, were obtained from ATCC between 2015 and 2018.

Techniques: Mutagenesis

Journal: Molecular cancer therapeutics

Article Title: Histone deacetylase inhibition has targeted clinical benefit in ARID1A mutated advanced urothelial carcinoma

doi: 10.1158/1535-7163.MCT-17-0957

Figure Lengend Snippet: Significantly enriched Hallmark gene sets in HT1197 cells treated with panobinostat for 48 hours

Article Snippet: Cell Culture Human bladder cancer cell lines HT1197, T24 and UMUC3, were obtained from ATCC between 2015 and 2018.

Techniques:

Journal: Molecular cancer therapeutics

Article Title: Histone deacetylase inhibition has targeted clinical benefit in ARID1A mutated advanced urothelial carcinoma

doi: 10.1158/1535-7163.MCT-17-0957

Figure Lengend Snippet: Cell cycle changes by flow cytometry using 12 nM panobinostat in A. HT1197, B. UMUC3, and C. T24 vs vehicle treatment for 24 hours. D. Changes in percent population of cells quantified by graph pad prizm. The change in the cell population distribution was replicated for a total of three times. An unpaired student t-test to compare the percent population with and without treatment showed the changes in G0/G1 and G2/M populations to be statistically significant. The error bars represent biological replicates.

Article Snippet: Cell Culture Human bladder cancer cell lines HT1197, T24 and UMUC3, were obtained from ATCC between 2015 and 2018.

Techniques: Flow Cytometry

Journal: Molecular cancer therapeutics

Article Title: Histone deacetylase inhibition has targeted clinical benefit in ARID1A mutated advanced urothelial carcinoma

doi: 10.1158/1535-7163.MCT-17-0957

Figure Lengend Snippet: A. Western blot to assess p21 levels in bladder cancer cell lines treated with panobinostat at 2 and 4 times the IC50 dose for 48 hours. This was repeated for a total of three times B. Western blot showing accumulation of gH2Ax marks in HT1197 upon treatment with panobinostat and belinostat. This was repeated for a total of three times. C. RT PCR to assess expression of TNFα, IFNβ1 and IFNα2 in HT1197 cells treated with panobinostat and belinostat. Results from three biological replicates are represented with error bars and the change in expression is tested for significance by the unpaired t-test (Graphpad Prism).

Article Snippet: Cell Culture Human bladder cancer cell lines HT1197, T24 and UMUC3, were obtained from ATCC between 2015 and 2018.

Techniques: Western Blot, Reverse Transcription Polymerase Chain Reaction, Expressing